66 ANTI-POLLUTION hydrolysis permits gel formation5 which
is difficult with Beta-glucans from other sources than mushroom.
Stability: The molecule as a high stability, important for cosmetic applications.5 Sericin protein part comes from a circular economy model, created in partnership with a traditional Italian silk factory, from Como. Sericin content in silk fibres is 20- 30% of the cocoon filament together with Fibroin. Silk sericin plays important roles in the spinning process of the silkworm and the construction of a robust cocoon shell. In Roelmi HPC’s process, sericin protein is isolated as a by-product from the production of silk. A side stream of gentle purification steps, with low temperature and moderate pH conditions, have been developed in order to obtain a high molecular weight sericin with impressive film-forming properties. It can reach 500 kDa, an exceptionally large size, which confers a bioactivity to the molecule that is lacking in smaller, degraded proteins from a standard strong purification process. Its high level of purity is obtained through a precisely controlled pharmaceutical grade manufacturing procedure able to obtain the integral protein, without performing any hydrolysis on the amino acidic chain and able to grant complete efficacy as performed by nature in terms of the silkworm’s protective barrier.
The two components, beta-glucan and
sericin, are synergised together in a water- based gel form, showing a great booster effect for both.
The use of Plerasan® Veil500 (now
referred to as ‘the natural active shield’) in all the safety tests performed in compliance to EU regulation 1223/2009 showed the absence of potential side effects; therefore considering it as safe when used in the customary or expected way.
The natural active shield supports skin
daily protection as: Antipollution agent Blue light protector Anti-age promoter
The natural active shield works as an active barrier on the skin: it creates a protective film, which shields the skin from external polluting agents, and at the same time, it rebalances the skin’s immune defence, in order to stay ready for possible stresses.
Development: evidence of in vitro efficacy
The evaluation of the protective effect against environmental pollutants, has been performed by in vitro & in vivo clinical tests done in an external and independent laboratory with Certified Quality Management System UNI EN ISO 9001:2008 and recognised as Testing Facility operating in GLP (Good Laboratory
PERSONAL CARE EUROPE
40 35 30 25 20 15 10 5 0
Cell Metabolism CTR– CTR+ Plerasan Veil500 Figure 2: Cell metabolism evaluation.
Practices – Dir 2004/9/EC and 2004/10/EC) by the Italian Ministry of Health. The in vitro study concerned the evaluation of the capability to protect reconstructed tissues of human epidermis against toxic effects of polluting agents. This evaluation was carried out by determination of cell viability, metabolism (protein synthesis) and lipoperoxidation after tissue treatment with the natural active shield in the presence of a standard urban dust containing polluting particulate matter. For test execution, reconstructed tissues of human epidermis (RHE model – by Sterlab) were treated for 24 hours with the pollution. In particular, the polluting powder was composed by selected polycyclic aromatic hydrocarbons (PAHs), nitro- substituted PAHs (nitro-PAHs), polychlorinated biphenyl (PCB) congeners, chlorinated pesticides and inorganic constituents in atmospheric particulate matter and similar matrices. Cell exposure to the natural active shield
was prolonged for 24 hours. At the end of the experimental period, cell viability was measured by MTT assay, together with the general metabolism of cells through protein dosage in culture medium and finally liporeroxidation, by means of malondialdeide dosage in tissue homogenate. The results were compared to negative control (tissues not treated, CTR-) and positive control (tissues treated only with urban dust, CTR +). The treatments were performed in triplicate. In summary:
Untreated cell culture (negative control, CTR-);
Cell culture in which environmental damage was experimentally induced with 25 μg/ml urban dust (positive control, CTR+);
Cell culture in which environmental damage was experimentally induced 25 μg/ml urban dust and simultaneously treated with the natural active shield.
Viability assay
Cell viability has been assessed by MTT test (3,(4,5-dimethylthiazol-2)2,5 difeniltetrazolium bromide). The assay is based on the intracellular reduction of the yellow tetrazolium salts by the mitochondrial enzyme succinate dehydrogenase in blue/purple formazan crystals. The reaction may therefore take place only in metabolically active cells and the value of the optical density obtained by photometric reading can be correlated to the amount of viable cells. At the end of each treatment the wells
were stained with MTT solution 0.5 mg/mL and incubated for three hours at 36.5°C / 5% CO2
. Then the wells were treated with
isopropanol and incubated for two hours at room temperature. After isopropanol incubation, absorbance readings were performed at 570 nm by microplate reader (isopropanol was used as blank for reading). For each test condition, the ratio of the average optical density of the treated cultures on the average optical density of negative controls determines the viability rate. Results are shown in Figure 1.
Cell metabolism study Protein content determination was carried out by Lowry colorimetric method on cell culture medium.
At the end of the treatment period, media were collected in order to determine the protein content. For each condition 5 μl of the medium were used. Three trials were performed for each determination. Results are shown in Figure 2.
February 2020
+28%
Protein content (µg)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92
